These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 28197947)

  • 1. Targeted Therapies in Elderly Patients with Metastatic Colorectal Cancer: A Review of the Evidence.
    Tapia Rico G; Townsend AR; Broadbridge V; Price TJ
    Drugs Aging; 2017 Mar; 34(3):173-189. PubMed ID: 28197947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New molecular targeting drugs for metastatic colorectal cancer].
    Komatsu Y; Harada K; Fukushima H; Yuki S
    Nihon Rinsho; 2014 Jan; 72(1):120-6. PubMed ID: 24597359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Chemotherapy with molecular targeting agents for colorectal cancer].
    Bando H; Ohtsu A
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():468-74. PubMed ID: 23513885
    [No Abstract]   [Full Text] [Related]  

  • 4. [Targeted therapies for metastatic colorectal cancer].
    Kito Y; Yamazaki K
    Nihon Rinsho; 2015 Aug; 73(8):1384-90. PubMed ID: 26281694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer: A systematic review and pooled analysis.
    Chebib R; Verlingue L; Cozic N; Faron M; Burtin P; Boige V; Hollebecque A; Malka D
    Semin Oncol; 2017 Apr; 44(2):114-128. PubMed ID: 28923209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New molecular-targeted agents for colorectal cancer - regorafenib and aflibercept].
    Kato S
    Gan To Kagaku Ryoho; 2013 Jan; 40(1):6-9. PubMed ID: 23306912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The value and effectiveness of angiogenesis inhibitors for colorectal cancer.
    Venook AP
    Clin Adv Hematol Oncol; 2015 Sep; 13(9):561-3. PubMed ID: 26452184
    [No Abstract]   [Full Text] [Related]  

  • 8. Emerging VEGF-receptor inhibitors for colorectal cancer.
    Martinelli E; Troiani T; Morgillo F; Orditura M; De Vita F; Belli G; Ciardiello F
    Expert Opin Emerg Drugs; 2013 Mar; 18(1):25-37. PubMed ID: 23216053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Navigating later lines of treatment for advanced colorectal cancer - optimizing targeted biological therapies to improve outcomes.
    Gill S; Dowden S; Colwell B; Collins LL; Berry S
    Cancer Treat Rev; 2014 Dec; 40(10):1171-81. PubMed ID: 25458604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current and advancing treatments for metastatic colorectal cancer.
    Sanz-Garcia E; Grasselli J; Argiles G; Elez ME; Tabernero J
    Expert Opin Biol Ther; 2016; 16(1):93-110. PubMed ID: 26549053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review and assessment of currently available data of the EGFR antibodies in elderly patients with metastatic colorectal cancer.
    Rosati G; Aprile G; Cardellino GG; Avallone A
    J Geriatr Oncol; 2016 Mar; 7(2):134-41. PubMed ID: 26897044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Angiogenic Pathways in Colorectal Cancer: Complexities, Challenges and Future Directions.
    Khan K; Cunningham D; Chau I
    Curr Drug Targets; 2017; 18(1):56-71. PubMed ID: 25808652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An oncology nurses' guide to new targeted agents for metastatic colorectal cancer.
    McIntyre K
    Clin J Oncol Nurs; 2015 Oct; 19(5):571-9. PubMed ID: 26414575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selection of biologics for patients with metastatic colorectal cancer: the role of predictive markers.
    Kasi PM; Hubbard JM; Grothey A
    Expert Rev Gastroenterol Hepatol; 2015 Mar; 9(3):273-6. PubMed ID: 25579664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: a clinician's perspective.
    Clarke JM; Hurwitz HI; Rangwala F
    Cancer Treat Rev; 2014 Oct; 40(9):1065-72. PubMed ID: 25047778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
    García-Alfonso P; Grande E; Polo E; Afonso R; Reina JJ; Jorge M; Campos JM; Martínez V; Angeles C; Montagut C
    Angiogenesis; 2014 Oct; 17(4):805-21. PubMed ID: 24793846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted therapy for metastatic colorectal cancer: role of aflibercept.
    Mitchell EP
    Clin Colorectal Cancer; 2013 Jun; 12(2):73-85. PubMed ID: 23102896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer.
    Köhne CH; Lenz HJ
    Oncologist; 2009 May; 14(5):478-88. PubMed ID: 19411318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there a benefit from addiction to anti-VEGF therapy in patients with colorectal cancer?
    Saif MW
    Anticancer Res; 2013 Jun; 33(6):2377-80. PubMed ID: 23749885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer.
    Heinemann V; Rivera F; O'Neil BH; Stintzing S; Koukakis R; Terwey JH; Douillard JY
    Eur J Cancer; 2016 Nov; 67():11-20. PubMed ID: 27592068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.